Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer

Trial Profile

Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Rebastinib (Primary) ; Eribulin; Paclitaxel
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2017 Trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 11 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top